



Johnson & Johnson Reports 2008 Second-Quarter Results:

Sales of \$16.5 Billion Increased 8.7% Versus a Year Ago; EPS was \$1.17 Excluding 2008 Special Items, Second-Quarter EPS of \$1.18 Increased 12.4%*

NEW BRUNSWICK, N.J., July 15, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Johnson & Johnson today announced record sales of \$16.5 billion for the second quarter of 2008, an increase of 8.7% as compared to the second quarter of 2007. Operational growth was 3.1% and the positive impact of currency was 5.6%. Domestic sales were up 2.1%, while international sales increased 16.2%, reflecting operational growth of 4.3% and a positive currency impact of 11.9%.

Net earnings and diluted earnings per share for the second quarter of 2008 were \$3.3 billion and \$1.17, respectively. The second quarter of 2008 included an after-tax in-process research and development charge of \$40 million associated with the acquisition of Amic, a developer of in vitro diagnostic technologies for use in Point-of-Care and near-patient settings. Excluding this charge, net earnings for the quarter of \$3.4 billion and diluted earnings per share of \$1.18 represent increases of 9.3% and 12.4%, respectively, as compared to the same period in 2007.* The Company increased its earnings guidance for full-year 2008 to \$4.45 - \$4.50 per share, which does not include the impact of any in-process research and development charges or other special items.

"Our solid earnings this quarter build on our strong track record of performance," said William C. Weldon, Chairman and Chief Executive Officer. "We are successfully managing through short-term pressures while continually making progress to enhance our long-term growth."

Worldwide Medical Devices and Diagnostics sales of \$6.1 billion for the second quarter represented a 12.1% increase over the prior year with operational growth of 5.7% and a positive impact from currency of 6.4%. Domestic sales increased 4.0%, while international sales increased 19.7%; 7.3% from operations and 12.4% from currency.

Primary contributors to the operational growth included Ethicon Endo-Surgery's minimally invasive products; DePuy's orthopaedic joint reconstruction, sports medicine and trauma businesses; Ethicon's surgical care products; Vistakon's disposable contact lenses; and Diabetes Care's blood glucose monitoring and insulin delivery products.

On July 1, 2008, the Company announced it received clearance of its ONETOUCH PING Glucose Management System by the U.S. Food and Drug Administration (FDA), the first full-feature insulin pump that wirelessly communicates with a blood glucose meter-remote.

Worldwide Consumer sales of \$4.0 billion for the second quarter represented a 13.2% increase over the prior year with operational growth of 6.8% and a positive impact from currency of 6.4%. Domestic sales increased 8.5%, while international sales increased 17.0%; 5.6% from operations and 11.4% from currency.

Sales results reflect the strong performance of the U.S. launch of ZYRTEC, an over-the-counter allergy treatment; LISTERINE antiseptic mouthrinse and whitening products; Baby Care products; and the skin care lines of NEUTROGENA, CLEAN & CLEAR, and AVEENO.

During the quarter, the Company received FDA approval of EVOLENCE, a new advanced collagen-based structural dermal filler for the correction of moderate to deep facial wrinkles and folds.

Worldwide Pharmaceutical sales of \$6.3 billion for the second quarter represented an increase over the prior year of 3.1% with an operational decline of 1.3% and a positive impact from currency of 4.4%. Domestic sales decreased 1.7%, while international sales increased 11.3%, which reflected an operational decline of 0.6% and a positive currency impact of 11.9%.

Sales growth reflects the strong performance of TOPAMAX, an antiepileptic and a treatment for the prevention of migraine headaches; VELCADE, a treatment for multiple myeloma; RISPERDAL CONSTA, an antipsychotic medication; and REMICADE in the U.S., a biologic approved for the treatment of a number of immune mediated inflammatory diseases.

Growth was negatively impacted by lower sales of PROCIT, a product for the treatment of anemia, due to a decline in the market. Sales results of RISPERDAL Oral, an antipsychotic medication, were negatively impacted by generic competition outside the U.S. and slowing sales ahead of the loss of marketing exclusivity on June 29, 2008, in the U.S. On June 30, 2008, the Company announced the launch of an authorized generic version of RISPERDAL Oral.

During the quarter, the Company announced that it received FDA approval of its Supplemental New Drug Application (sNDA) for CONCERTA, for the treatment of Attention Deficit Hyperactivity Disorder in adults. In addition, the Company submitted a Biologics License Application to the FDA requesting the approval of golimumab (CNTO 148) as a monthly subcutaneous treatment for adults with active forms of rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. The Company also filed an sNDA requesting pediatric exclusivity for TOPAMAX.

About Johnson & Johnson

Caring for the world, one person at a time ... inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Our 120,200 employees at more than 250 Johnson & Johnson companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.

* Net earnings and diluted earnings per share excluding special items, such as after-tax in-process research and development charges, are non-GAAP financial measures and should not be considered replacements for GAAP results. For a reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measures, see the accompanying tables to this release.

NOTE TO INVESTORS

Johnson & Johnson will conduct a conference call with financial analysts to discuss this news release today at 8:30 a.m., Eastern Time. A simultaneous webcast of the call for investors and other interested parties may be accessed by visiting the Johnson & Johnson website at www.investor.jnj.com. A replay and podcast will be available approximately two hours after the live webcast by visiting www.investor.jnj.com.

Copies of the financial schedules accompanying this press release are available at www.investor.jnj.com/historical-sales.cfm. The schedules include supplementary sales data, a condensed consolidated statement of earnings, and sales of key products/franchises. Additional information on Johnson & Johnson can be found on the Company's website at www.jnj.com.

(This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Johnson & Johnson's expectations and projections. Risks and uncertainties include general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of the Company's Annual Report on Form 10-K for the fiscal year ended December 30, 2007. Copies of this Form 10-K, as well as subsequent filings, are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statements as a result of new information or future events or developments.)

Johnson & Johnson and Subsidiaries Supplementary Sales Data

(Unaudited; Dollars in Millions)

	SECOND QUARTER				
	2008	2007	Total	Percent Change Operations	Currency
Sales to customers by segment of business					
Consumer					
U.S.	\$1,694	1,562	8.5%	8.5	-
International	2,342	2,002	17.0	5.6	11.4
	4,036	3,564	13.2	6.8	6.4
Pharmaceutical					
U.S.	3,793	3,860	(1.7)	(1.7)	-
International	2,547	2,289	11.3	(0.6)	11.9
	6,340	6,149	3.1	(1.3)	4.4

Med Devices & Diagnostics					
U.S.	2,723	2,619	4.0	4.0	-
International	3,351	2,799	19.7	7.3	12.4
	6,074	5,418	12.1	5.7	6.4
U.S.	8,210	8,041	2.1	2.1	-
International	8,240	7,090	16.2	4.3	11.9
Worldwide	\$16,450	15,131	8.7%	3.1	5.6

(Unaudited; Dollars in Millions)

	2008	2007	SIX MONTHS		
			Total	Percent Change Operations	Currency
Sales to customers by segment of business					
Consumer					
U.S.	3,513	3,191	10.1%	10.1	-
International	4,587	3,869	18.6	7.0	11.6
	8,100	7,060	14.7	8.3	6.4
Pharmaceutical					
U.S.	7,863	7,894	(0.4)	(0.4)	-
International	4,906	4,476	9.6	(1.8)	11.4
	12,769	12,370	3.2	(0.9)	4.1
Med Devices & Diagnostics					
U.S.	5,311	5,203	2.1	2.1	-
International	6,464	5,535	16.8	5.0	11.8
	11,775	10,738	9.7	3.6	6.1
U.S.	16,687	16,288	2.4	2.4	-
International	15,957	13,880	15.0	3.4	11.6
Worldwide	\$32,644	30,168	8.2%	2.8	5.4

Johnson & Johnson and Subsidiaries
Supplementary Sales Data

(Unaudited; Dollars in Millions)

	2008	2007	SECOND QUARTER		
			Total	Percent Change Operations	Currency
Sales to customers by geographic area					
U.S.	\$8,210	8,041	2.1%	2.1	-
Europe	4,547	3,907	16.4	2.4	14.0
Western Hemisphere excluding U.S.	1,280	1,131	13.2	3.3	9.9
Asia-Pacific, Africa	2,413	2,052	17.6	8.5	9.1
International	8,240	7,090	16.2	4.3	11.9
Worldwide	\$16,450	15,131	8.7%	3.1	5.6

(Unaudited; Dollars in Millions)

	2008	2007	SIX MONTHS		
			Total	Percent Change Operations	Currency

Sales to customers by geographic area					
U.S.	\$16,687	16,288	2.4%	2.4	-
Europe	8,855	7,720	14.7	1.6	13.1
Western Hemisphere excluding U.S.	2,525	2,177	16.0	4.7	11.3
Asia-Pacific, Africa	4,577	3,983	14.9	5.9	9.0
International	15,957	13,880	15.0	3.4	11.6
Worldwide	\$32,644	30,168	8.2%	2.8	5.4

Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings

(Unaudited; in Millions Except
Per Share Figures)

SECOND QUARTER

	2008		2007		Percent Increase (Decrease)
	Amount	Percent to Sales	Amount	Percent to Sales	
Sales to customers	\$16,450	100.0	\$15,131	100.0	8.7
Cost of products sold	4,751	28.9	4,358	28.8	9.0
Selling, marketing and administrative expenses	5,507	33.5	5,029	33.3	9.5
Research expense	1,896	11.5	1,866	12.3	1.6
In-process research & development	40	0.2	-	-	
Interest (income) expense, net	16	0.1	(36)	(0.2)	
Other (income) expense, net	(135)	(0.8)	(117)	(0.8)	
Earnings before provision for taxes on income	4,375	26.6	4,031	26.6	8.5
Provision for taxes on income	1,048	6.4	950	6.2	10.3
Net earnings	\$3,327	20.2	\$3,081	20.4	8.0
Net earnings per share (Diluted)	\$1.17		\$1.05		11.4
Average shares outstanding (Diluted)	2,844.8		2,922.5		
Effective tax rate	24.0%		23.6%		
Adjusted earnings before provision for taxes and net earnings					
Earnings before provision for taxes on income	\$4,415(1)	26.8	\$4,031	26.6	9.5
Net earnings	\$3,367(1)	20.5	\$3,081	20.4	9.3

Net earnings per share (Diluted)	\$1.18(1)	\$1.05	12.4
Effective tax rate	23.7%	23.6%	

(1) The difference between as reported earnings before provision for taxes on income and net earnings and net earnings per share (diluted) is IPR&D of \$40 million with no tax benefit and \$0.01 per share, respectively.

Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings

(Unaudited; in Millions
Except Per Share Figures)

SIX MONTHS

	2008		2007		Percent Increase (Decrease)
	Amount	Percent to Sales	Amount	Percent to Sales	
Sales to customers	\$32,644	100.0	\$30,168	100.0	8.2
Cost of products sold	9,365	28.7	8,743	29.0	7.1
Selling, marketing and administrative expenses	10,630	32.6	9,831	32.5	8.1
Research expense	3,608	11.1	3,518	11.7	2.6
In-process research & development	40	0.1	807	2.7	
Interest (income) expense, net	32	0.1	(69)	(0.2)	
Other (income) expense, net	(153)	(0.5)	(345)	(1.1)	
Earnings before provision for taxes on income	9,122	27.9	7,683	25.4	18.7
Provision for taxes on income	2,197	6.7	2,029	6.7	8.3
Net earnings	\$6,925	21.2	\$5,654	18.7	22.5
Net earnings per share (Diluted)	\$2.43		\$1.93		25.9
Average shares outstanding (Diluted)	2,856.1		2,924.9		
Effective tax rate	24.1%		26.4%		
Adjusted earnings before provision for taxes and net earnings					
Earnings before provision for taxes on income	\$9,162(1)	28.1	\$8,490(2)	28.1	7.9
Net earnings	\$6,965(1)	21.3	\$6,461(2)	21.4	7.8
Net earnings per share (Diluted)	\$2.44(1)		\$2.21(2)		10.4
Effective tax rate	24.0%		23.9%		

(1) The difference between as reported earnings before provision for taxes on income and net earnings and net earnings per share (diluted) is IPR&D of \$40 million with no tax benefit and \$0.01 per share, respectively.

(2) The difference between as reported earnings before provision for taxes on income and net earnings and net earnings per share (diluted) is IPR&D of \$807 million with no tax benefit and \$0.28 per share, respectively.

REPORTED SALES vs. PRIOR PERIOD
\$MM

SECOND QUARTER

% Change

	2008	2007	Reported	Operational (1)	Currency
PHARMACEUTICAL SEGMENT (2) (3)					
ACIPHEX/PARIET					
US	153	161	-5.0%	-5.0%	-
Intl	172	175	-1.7%	-11.8%	10.1%
WW	325	336	-3.3%	-8.6%	5.3%
CONCERTA					
US	208	199	4.5%	4.5%	-
Intl	71	57	24.6%	12.6%	12.0%
WW	279	256	9.0%	6.3%	2.7%
DURAGESIC/FENTANYL TRANSDERMAL					
US	70	96	-27.1%	-27.1%	-
Intl	202	192	5.2%	-6.6%	11.8%
WW	272	288	-5.6%	-13.5%	7.9%
LEVAQUIN/FLOXIN					
US	330	344	-4.1%	-4.1%	-
Intl	21	20	5.0%	-0.2%	5.2%
WW	351	364	-3.6%	-3.9%	0.3%
PROCRI/EXPRES					
US	346	449	-22.9%	-22.9%	-
Intl	306	309	-1.0%	-12.7%	11.7%
WW	652	758	-14.0%	-18.8%	4.8%
RAZADYNE/REMINYL					
US	42	51	-17.6%	-17.6%	-
Intl	110	81	35.8%	19.7%	16.1%
WW	152	132	15.2%	5.4%	9.8%
REMICADE					
US	684	625	9.4%	9.4%	-
US Exports (4)	200	244	-18.0%	-18.0%	-
Intl	2	-	100.0%	100.0%	-
WW	886	869	2.0%	2.0%	-
RISPERDAL					
US	492	540	-8.9%	-8.9%	-

Intl	220	308	-28.6%	-36.6%	8.0%
WW	712	848	-16.0%	-18.9%	2.9%
RISPERDAL CONSTA					
US	120	102	17.6%	17.6%	-
Intl	223	176	26.7%	12.2%	14.5%
WW	343	278	23.4%	14.2%	9.2%
TOPAMAX					
US	548	472	16.1%	16.1%	-
Intl	129	106	21.7%	9.3%	12.4%
WW	677	578	17.1%	14.8%	2.3%
VELCADE					
US	1	1	-	-	-
Intl	204	125	63.2%	47.0%	16.2%
WW	205	126	62.7%	46.8%	15.9%
OTHER					
US	599	576	4.0%	4.0%	-
Intl	887	740	19.9%	5.0%	14.9%
WW	1,486	1,316	12.9%	4.5%	8.4%
TOTAL PHARMACEUTICAL					
US	3,793	3,860	-1.7%	-1.7%	-
Intl	2,547	2,289	11.3%	-0.6%	11.9%
WW	6,340	6,149	3.1%	-1.3%	4.4%

SIX MONTHS

% Change

	2008	2007	Reported	Operational (1)	Currency
PHARMACEUTICAL SEGMENT (2) (3)					
ACIPHEX/PARIET					
US	269	320	-15.9%	-15.9%	-
Intl	333	352	-5.4%	-15.7%	10.3%
WW	602	672	-10.4%	-15.8%	5.4%
CONCERTA					
US	432	399	8.3%	8.3%	-
Intl	137	109	25.7%	13.7%	12.0%
WW	569	508	12.0%	9.4%	2.6%
DURAGESIC/FENTANYL TRANSDERMAL					
US	145	212	-31.6%	-31.6%	-
Intl	360	379	-5.0%	-15.3%	10.3%
WW	505	591	-14.6%	-21.2%	6.6%
LEVAQUIN/FLOXIN					
US	804	803	0.1%	0.1%	-
Intl	43	40	7.5%	2.0%	5.5%
WW	847	843	0.5%	0.2%	0.3%
PROCRIT/EXPRES					
US	680	979	-30.5%	-30.5%	-
Intl	601	596	0.8%	-11.1%	11.9%

WW	1,281	1,575	-18.7%	-23.2%	4.5%
RAZADYNE/REMINYL					
US	92	102	-9.8%	-9.8%	-
Intl	209	158	32.3%	16.8%	15.5%
WW	301	260	15.8%	6.4%	9.4%
REMICADE					
US	1,360	1,225	11.0%	11.0%	-
US Exports (4)	520	375	38.7%	38.7%	-
Intl	4	-	100.0%	100.0%	-
WW	1,884	1,600	17.8%	17.8%	-
RISPERDAL					
US	1,074	1,099	-2.3%	-2.3%	-
Intl	447	616	-27.4%	-35.1%	7.7%
WW	1,521	1,715	-11.3%	-14.1%	2.8%
RISPERDAL CONSTA					
US	221	203	8.9%	8.9%	-
Intl	431	336	28.3%	13.9%	14.4%
WW	652	539	21.0%	12.0%	9.0%
TOPAMAX					
US	1,068	973	9.8%	9.8%	-
Intl	255	215	18.6%	6.7%	11.9%
WW	1,323	1,188	11.4%	9.3%	2.1%
VELCADE					
US	3	3	-	-	-
Intl	386	236	63.6%	48.4%	15.2%
WW	389	239	62.8%	47.8%	15.0%
OTHER					
US	1,195	1,201	-0.5%	-0.5%	-
Intl	1,700	1,439	18.1%	3.8%	14.3%
WW	2,895	2,640	9.7%	1.9%	7.8%
TOTAL PHARMACEUTICAL					
US	7,863	7,894	-0.4%	-0.4%	-
Intl	4,906	4,476	9.6%	-1.8%	11.4%
WW	12,769	12,370	3.2%	-0.9%	4.1%

- (1) Operational growth excludes the effect of currency
- (2) Select areas (unaudited)
- (3) Prior year amounts have been reclassified to conform with current presentation
- (4) For external purposes, reported as U.S. sales

SECOND QUARTER

% Change

2008 2007 Reported Operational (1) Currency

MEDICAL DEVICES AND
DIAGNOSTICS (2) (3)

CORDIS (4)					
US	348	397	-12.3%	-12.3%	-
Intl	504	455	10.8%	-1.1%	11.9%
WW	852	852	0.0%	-6.4%	6.4%
DEPUY					
US	702	663	5.9%	5.9%	-
Intl	587	472	24.4%	12.2%	12.2%
WW	1,289	1,135	13.6%	8.5%	5.1%
DIABETES CARE					
US	338	310	9.0%	9.0%	-
Intl	336	286	17.5%	4.1%	13.4%
WW	674	596	13.1%	6.7%	6.4%
ETHICON (5)					
US	374	351	6.6%	6.6%	-
Intl	646	553	16.8%	5.1%	11.7%
WW	1,020	904	12.8%	5.7%	7.1%
ETHICON ENDO-SURGERY					
US	484	454	6.6%	6.6%	-
Intl	640	503	27.2%	13.4%	13.8%
WW	1,124	957	17.5%	10.4%	7.1%
ORTHO-CLINICAL DIAGNOSTICS (5)					
US	250	231	8.2%	8.2%	-
Intl	226	190	18.9%	6.3%	12.6%
WW	476	421	13.1%	7.4%	5.7%
VISION CARE					
US	227	213	6.6%	6.6%	-
Intl	412	340	21.2%	9.5%	11.7%
WW	639	553	15.6%	8.4%	7.2%
TOTAL MEDICAL DEVICES AND DIAGNOSTICS					
US	2,723	2,619	4.0%	4.0%	-
Intl	3,351	2,799	19.7%	7.3%	12.4%
WW	6,074	5,418	12.1%	5.7%	6.4%

SIX MONTHS

% Change

	2008	2007	Reported	Operational (1)	Currency
MEDICAL DEVICES AND DIAGNOSTICS (2) (3)					
CORDIS (4)					
US	705	821	-14.1%	-14.1%	-
Intl	982	959	2.4%	-8.3%	10.7%
WW	1,687	1,780	-5.2%	-11.0%	5.8%
DEPUY					
US	1,396	1,341	4.1%	4.1%	-
Intl	1,146	951	20.5%	8.8%	11.7%
WW	2,542	2,292	10.9%	6.1%	4.8%

DIABETES CARE					
US	641	602	6.5%	6.5%	-
Intl	648	543	19.3%	5.9%	13.4%
WW	1,289	1,145	12.6%	6.2%	6.4%
ETHICON (5)					
US	715	696	2.7%	2.7%	-
Intl	1,250	1,082	15.5%	4.0%	11.5%
WW	1,965	1,778	10.5%	3.5%	7.0%
ETHICON ENDO-SURGERY					
US	913	871	4.8%	4.8%	-
Intl	1,214	977	24.3%	11.3%	13.0%
WW	2,127	1,848	15.1%	8.3%	6.8%
ORTHO-CLINICAL DIAGNOSTICS (5)					
US	488	464	5.2%	5.2%	-
Intl	431	365	18.1%	5.8%	12.3%
WW	919	829	10.9%	5.5%	5.4%
VISION CARE					
US	453	408	11.0%	11.0%	-
Intl	793	658	20.5%	9.3%	11.2%
WW	1,246	1,066	16.9%	10.0%	6.9%
TOTAL MEDICAL DEVICES AND DIAGNOSTICS					
US	5,311	5,203	2.1%	2.1%	-
Intl	6,464	5,535	16.8%	5.0%	11.8%
WW	11,775	10,738	9.7%	3.6%	6.1%

(1) Operational growth excludes the effect of currency

(2) Select areas (unaudited)

(3) Prior year amounts have been reclassified to conform with current presentation

(4) Includes sales of Drug-Eluting Stents for Q2 2008 of \$167, \$227 and \$394 million Domestic, International and Worldwide respectively

Includes sales of Drug-Eluting Stents for Q2 2007 of \$209, \$234 and \$443 million Domestic, International and Worldwide respectively

Includes sales of Drug-Eluting Stents for June YTD 2008 of \$336, \$458 and \$794 million Domestic, International and Worldwide respectively

Includes sales of Drug-Eluting Stents for June YTD 2007 of \$445, \$526 and \$971 million Domestic, International and Worldwide respectively

(5) Restated to include portion of sales previously reported in the "Other" category

SECOND QUARTER

% Change

2008 2007 Reported Operational (1) Currency

CONSUMER SEGMENT (2)

SKIN CARE					
US	379	338	12.1%	12.1%	-
Intl	460	419	9.8%	-1.1%	10.9%
WW	839	757	10.8%	4.7%	6.1%
BABY CARE					
US	111	106	4.7%	4.7%	-
Intl	461	381	21.0%	10.5%	10.5%
WW	572	487	17.5%	9.3%	8.2%
ORAL CARE					
US	185	186	-0.5%	-0.5%	-
Intl	223	168	32.7%	20.8%	11.9%
WW	408	354	15.3%	9.7%	5.6%
OTC/NUTRITIONALS					
US	679	584	16.3%	16.3%	-
Intl	726	622	16.7%	5.1%	11.6%
WW	1,405	1,206	16.5%	10.5%	6.0%
WOMEN'S HEALTH					
US	158	163	-3.1%	-3.1%	-
Intl	346	300	15.3%	3.3%	12.0%
WW	504	463	8.9%	1.1%	7.8%
WOUND CARE / OTHER					
US	182	185	-1.6%	-1.6%	-
Intl	126	112	12.5%	0.6%	11.9%
WW	308	297	3.7%	-0.8%	4.5%
TOTAL CONSUMER					
US	1,694	1,562	8.5%	8.5%	-
Intl	2,342	2,002	17.0%	5.6%	11.4%
WW	4,036	3,564	13.2%	6.8%	6.4%

SIX MONTHS

% Change

	2008	2007	Reported	Operational (1)	Currency
CONSUMER SEGMENT (2)					
SKIN CARE					
US	761	695	9.5%	9.5%	-
Intl	918	826	11.1%	0.1%	11.0%
WW	1,679	1,521	10.4%	4.4%	6.0%
BABY CARE					
US	226	215	5.1%	5.1%	-
Intl	879	719	22.3%	11.7%	10.6%
WW	1,105	934	18.3%	10.1%	8.2%
ORAL CARE					
US	384	389	-1.3%	-1.3%	-
Intl	410	324	26.5%	15.3%	11.2%
WW	794	713	11.4%	6.3%	5.1%
OTC/NUTRITIONALS					
US	1,521	1,239	22.8%	22.8%	-

Intl	1,478	1,224	20.8%	8.4%	12.4%
WW	2,999	2,463	21.8%	15.7%	6.1%
WOMEN'S HEALTH					
US	306	326	-6.1%	-6.1%	-
Intl	659	558	18.1%	5.9%	12.2%
WW	965	884	9.2%	1.5%	7.7%
WOUND CARE / OTHER					
US	315	327	-3.7%	-3.7%	-
Intl	243	218	11.5%	-0.3%	11.8%
WW	558	545	2.4%	-2.3%	4.7%
TOTAL CONSUMER					
US	3,513	3,191	10.1%	10.1%	-
Intl	4,587	3,869	18.6%	7.0%	11.6%
WW	8,100	7,060	14.7%	8.3%	6.4%

(1) Operational growth excludes the effect of currency

(2) Select areas (unaudited)

SOURCE Johnson & Johnson

<http://www.jnj.com/>

Copyright (C) 2008 PR Newswire. All rights reserved

News Provided by COMTEX